

Haematologica
HAEMATOL/2017/186890
Version 3

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485

Alice S. Mims, Anjali Mishra, Shelley Orwick, James Blachly, Rebecca B. Klisovic, Ramiro Garzon, Alison R. Walker, Steven M. Devine, Katherine J. Walsh, Sumithira Vasu, Susan Whitman, Guido Marcucci, Daniel Jones, Nyla A. Heerema, Gerard Lozanski, Michael A. Caligiuri, Clara D. Bloomfield, John C. Byrd, Richard Piekarz, Michael R. Grever, and William Blum

Disclosures: 1. U01 CA76576-05, P30 CA016058 and SPORE P50-CA140158 2. Susan P. Whitman - Has been an employee of Eli Lilly & Company since May 2016 but contributions to manuscript were during her tenure at The Ohio State University. None for all other authors. 3. None for all authors.

Contributions: ASM and WB performed data analysis. SO, AM, JB, DJ, SW, NH, and GL performed molecular and cytogenetic analysis. RBK, RG, ARW, SMD, KJW, SV, GM, JCB, and WB enrolled and supervised patients on study. WB, MRG, and RP supervised the study. WB, GM, RG, MAC, CDB, and MRG contributed to study design. AM and WB wrote the manuscript.